Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 9,648

Document Document Title
WO/2022/204777A1
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations...  
WO/2022/206922A1
The present invention relates to the field of nucleic acid sequencing. Specifically, provided in the present invention is a nucleotide analogue for sequencing. The nucleotide analogue carries a linker on the base or the ribose ring 3'-OH...  
WO/2022/208508A1
The present invention provides a scalable two-step synthesis of molnupiravir. The reaction sequence involves the use of commercially easily available cytidine (1), and molnupiravir is formed through direct hydroxy amination of the cytidi...  
WO/2022/211627A1
This invention relates to compounds that are useful as inhibitors, in particular as inhibitors of Nicotinamide N-methyltransferase (NNMT), and formulations composing such compounds. The compounds and formulations may be used as a medicam...  
WO/2022/212230A1
The present invention relates to efficient processes useful in the preparation of fluorinated cyclic dinucleosides, such as [P(R)]-2'-deoxy-2'-fluoro-5'-O-[(R)-hydroxymercaptophosphiny l]-P-thio-β-D-arabino-adenylyl-(3'→5')-3'-deoxy-3...  
WO/2022/204770A1
The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations...  
WO/2022/203427A1
The present invention relates to: an adenosine derivative capable of acting as an antagonist on A2A and A3 adenosine receptors through the introduction of substituents into carbons at the 2nd and 8th positions and 6th and/or 9th amine(s)...  
WO/2022/194924A1
This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphoro...  
WO/2022/189846A1
The present invention relates to medicine, and in particular to the treatment of viral infections, more particularly to inhibitors of viral mRNA cap methyltransf erases (MTases). Even more particularly, the invention relates to adenosylm...  
WO/2022/190915A1
Provided are: a novel compound having improved in-vivo efficacy and antitumor activity of a curcumin derivative, or a salt thereof; and an antitumor activator containing the same as an active ingredient. The present invention is a compou...  
WO/2022/189459A2
The present invention relates to beta D-galactopyranose compound of formula (I). Wherein the pyranose ring is β-D-galactopyranose, and these compounds are high affinity galectin-3 inhibitors for use in treatment of inflammation; fibrosi...  
WO/2022/188903A1
The present disclosure relates to 3'3' cyclic dinucleotides containing isonucleotidic units, their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceu...  
WO/2022/187312A1
The present disclosure provides a process of separating designated oligomeric compounds from sample solutions comprising at least one contaminant. In certain embodiments, the designated oligomeric compounds comprise a modified oligonucle...  
WO/2022/183281A1
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...  
WO/2022/182604A1
The invention relates to compounds of Formula (I), salts thereof, pharmaceutical compositions thereof, as well as methods of treating or preventing HIV in subjects.  
WO/2022/183066A1
The present application is directed to, in part, nucleotide analogs with a novel design of a 3'-OH reversible terminator that comprises an enzyme-cleavable linkage.  
WO/2022/183109A1
An electroporation buffer comprising: a solvent; a sugar; a chloride salt; and a buffering agent. In certain embodiments: the solvent is water; the sugar is glucose or mannitol; the chloride salt is potassium chloride (KCl) or magnesium ...  
WO/2022/175685A1
The present invention relates to a compound according to Formula (la) or (lb) wherein R1; R3; Y and X are defined herein, and their use in methods of nucleic acid synthesis. Disclosed herein is a method of reducing the deamination of the...  
WO/2022/174351A1
Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharm...  
WO/2022/175684A1
The present invention relates to a compound according to Formula (1a) or (1b): wherein R1; R2; R3 X and Y are defined herein, and their use in methods of nucleic acid synthesis.  
WO/2022/171561A1
The present invention relates to a D-galactopyranose compound of formula (1) wherein the pyranose ring is beta-D-galactopyranose, and these compounds are high affinity galectin-1 and/or 3 inhibitors for use in treatment of inflammation; ...  
WO/2022/174194A1
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...  
WO/2022/168106A1
Disclosed herein is a process for synthesis of Molnupiravir from cytidine of using a lipase for esterification reaction. The process comprises of reacting compound of formula II with acetone in presence of sulphuric acid to obtain compou...  
WO/2022/168107A1
Disclosed herein is the enzymatic process for synthesis of Molnupiravir intermediate, 5'-isobutylester of cytidine acetonide. The process employs cytidine acetonide as starting material to prepare 5'-isobutylester of cytidine acetonide. ...  
WO/2022/166581A1
A nucleotide derivative, a pharmaceutical composition thereof, and a use thereof. Specifically disclosed are a nucleotide derivative represented by formula (I) or a tautomer, a stereoisomer, a solvate, a pharmaceutically acceptable salt ...  
WO/2022/163764A1
Provided is a method for producing an imidazopyridine derivative represented by formula (I), wherein, in formula (I), X is H, a substituted or unsubstituted propenyl group, a substituted or unsubstituted propinyl group, or a substituted ...  
WO/2022/165358A1
A process is provided for microencapsulating nicotinamide riboside (NR), and other NR derivatives by using ethyl cellulose which may be polymerized in a particular manner. Further, compositions comprising NR or derivatives thereof microe...  
WO/2022/164941A1
Advantageous isolated morphic Form III of the hemi-sulfate salt of AT-527 that exhibits a faster rate of dissolution over the amorphous form leading to increased bioavailability and thus efficacy for therapeutic administration in a solid...  
WO/2022/163846A1
The purpose of the present invention is to provide: a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate; and a production intermediate thereof. Another...  
WO/2022/159872A1
Disclosed herein are adenosine derivative prodrugs and compositions thereof that can be used for the treatment of HIV infection or RNA virus infection.  
WO/2022/159877A1
The present disclosure is directed to methods of treating or preventing RNA virus infections and retroviral diseases, such as HIV and AIDS, comprising administering to a subject in need an effective amount of (a) a capsid inhibitor and (...  
WO/2022/159811A1
This invention provides compounds of Formulae (I), (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention fu...  
WO/2022/157173A1
The present invention relates to methods of making a nicotinamide ribofuranoside salt, in particular a crystalline nicotinamide ribofuranoside salt, via salt metathesis comprising subjecting nicotinamide ribofuranoside hydrogen malate or...  
WO/2022/147223A2
This invention relates to an oligonucleotide comprising one or more 2'-modified nucleosides, wherein the 2'-position of the nucleoside has a structure of formula (I). The invention also relates to a pharmaceutical composition comprising ...  
WO/2022/143740A1
Provided are a compound having both regulatory or agonist effects on adenosine A3 receptor activity, a method for preparing the series of compounds, a pharmaceutical composition of the series of compounds, and the medical use of the seri...  
WO/2022/140365A1
Provided herein, are compositions comprising GalNAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment ...  
WO/2022/133205A1
The present invention relates to efficient synthetic processes useful in the preparation of antiviral nucleosides, particularly uridine 4-oxime 5'-(2-methylpropanoate) {(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyimino)-2-oxo-3,4-d ihydropy...  
WO/2022/127914A1
The invention concerns compounds of formula (I) which modulate, especially agonize alpha kinase 1 (ALPK1) and are useful for treating a condition, disease or disorder in which a decrease or increase in ALPK1 activity contributes to the p...  
WO/2022/127920A1
Provided in the present invention are a preparation method for and an intermediate of a 5'-nucleoside prodrug. Specifically, provided in the present invention is a method for preparing a compound of formula VI. The method comprises the s...  
WO/2022/131350A1
The purpose of the present invention is to overcome problems in the acquisition of a DNA aptamer in the conventional methods, including the lack of variety of interactions with target molecules, the increase in the cost for aptamer acqui...  
WO/2022/129930A1
The present application relates to alkylpyridinium substituted coumarin dyes of formula (I) and their uses as fluorescent labels. For example, these dyes may be used to label nucleotides for nucleic acid sequencing applications. wherein ...  
WO/2022/123432A1
Provided herein are compositions for use in treatment of cancer comprising a therapeutically effective amount of harmine or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of cordycepin. ...  
WO/2022/123501A1
The invention provides compounds of the Formula (I) or the Formula (Ia) which are useful intermediates in the synthesis of potential antiviral drugs such as 3'-deoxy-3',4'-didehydro-cytidine triphosphate (ddhCTP).  
WO/2022/125735A1
The disclosure provides processes for preparing the compound of formula (VIII) and pharmaceutically acceptable salts thereof. Intermediates useful in preparing the compound of formula (VIII) are also provided.  
WO/2022/124410A1
Provided are cytosine-type crosslinked nucleoside amidite crystals represented by a structural formula. In the formula, R2 and R2 are substitution groups and R3 is a protector group.  
WO/2022/125031A1
The invention relates to trimethyl chitosan nanoparticles containing magnetic -targeted gemcitabine developed for use in the treatment of lung cancer.  
WO/2022/119784A1
5' -O-Phenylacetyluridine effectively delivers both phenylacetate and uridine to a subject. It can be used to treat hepatic encephalopathy and genetic disorders of the hepatic nitrogen cycle.  
WO/2022/109741A1
CD73 (also known as ecto-5´-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune...  
WO/2022/114105A1
The present invention addresses the problem of a providing NMN having high purity and a low impurity content. The present invention is a high-purity β-nicotinamide mononucleotide (NMN) which has a purity of 99.0 mass% or higher and in...  
WO/2022/109551A1
The present invention relates to compounds and methods useful for inhibiting non-receptor tyrosine-protein kinase Src ("Src"). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present inven...  

Matches 201 - 250 out of 9,648